Tofacitinib-Induced Acute Pancreatitis in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature
- PMID: 39234906
- DOI: 10.2174/0115748863300565240819114551
Tofacitinib-Induced Acute Pancreatitis in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature
Abstract
Background: Acute Pancreatitis (AP) is an uncommon complication that rarely occurs during Rheumatoid Arthritis (RA). Among the varied etiologies of AP, Drug-induced Pancreatitis (DIP) remains a rare entity and a rather challenging condition. A large panel of drugs have been reported to cause pancreatitis; however, there are no cases of tofacitinib-induced pancreatitis reported in the literature.
Case presentation: We have, herein, reported the case of a Tunisian 58-year-old woman with a four-year history of RA who experienced two episodes of AP; the first one occurred on the second day of a 3-day series of methylprednisolone intravenous injections, and the second episode occurred on the sixth-day of tofacitinib administration. Each time, she presented acute abdominal pain with characteristic radiation to the back. Symptoms resolved spontaneously once the suspected drug was discontinued. In the event of a negative investigation, including abdominal ultrasonography and magnetic resonance imaging, and assessment of albumin, calcemia, triglyceridemia, serum ferritin, and IgG4 levels, DIP was the most likely diagnosis.
Conclusion: Although DIP is still a rare condition, it remains serious with an increased risk of mortality. We intended to alert clinicians that in addition to the known side effects of tofacitinib, pancreatitis may be induced by this drug, especially in predisposed patients.
Keywords: Case report; adverse effects.; corticosteroids; drug-induced pancreatitis; janus kinase inhibitors; pancreatitis; rheumatoid arthritis; tofacitinib.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.Arthritis Care Res (Hoboken). 2017 Apr;69(4):592-598. doi: 10.1002/acr.23004. Arthritis Care Res (Hoboken). 2017. PMID: 27565000 Free PMC article. Clinical Trial.
-
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.Ann Rheum Dis. 2016 May;75(5):831-41. doi: 10.1136/annrheumdis-2014-205847. Epub 2015 Apr 22. Ann Rheum Dis. 2016. PMID: 25902789 Free PMC article.
-
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.Arthritis Res Ther. 2018 Mar 23;20(1):60. doi: 10.1186/s13075-018-1539-6. Arthritis Res Ther. 2018. PMID: 29566769 Free PMC article.
-
[Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):443-7. doi: 10.2177/jsci.38.443. Nihon Rinsho Meneki Gakkai Kaishi. 2015. PMID: 27118331 Review. Japanese.
-
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.Ann Rheum Dis. 2016 Jun;75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28. Ann Rheum Dis. 2016. PMID: 26318385 Free PMC article. Review.
Cited by
-
Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis.Front Pharmacol. 2025 Jun 9;16:1524214. doi: 10.3389/fphar.2025.1524214. eCollection 2025. Front Pharmacol. 2025. PMID: 40552144 Free PMC article.
References
-
- Jones M.R.; Hall O.M.; Kaye A.M.; Kaye A.D.; Drug-induced acute pancreatitis: A review. Ochsner J 2015,15(1),45-51 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical